Presentation: 2024 ND EPSCoR Annual conference
November 21, 2024, Alerus Center, Grand Forks, North Dakota
Azobenzene-incorporated Polymersomes for Control of Targeted Drug Delivery to Triple-Negative Breast Cancer
George
Davisson
Undergraduate Student
Mayville State University
Co-author: Rayat Hossain, NDSU
Session
Poster Session B
Poster #41
Introduction Results Conclusion Cont. Triple-negative breast cancer (TNBC) is a very aggressive form of breast cancer. It accounts for 15%-20% of breast cancer cases.1 Patients with TNBC have the worst prognosis. Their prognosis is caused by Hypoxia which is a result of poor angiogenesis.2 The most common treatment is Doxorubicin (Dox) but when used alone, can often diminish the patient’s quality of life.3 Using polymersomes, which are small nanovesicles, Dox can reach the hypoxic area directly without any systemic damage.4 This study will focus on using polymersomes with different hypoxic linkers, which should theoretically release the contents in the hypoxic area at differing rates based on their specific linkers. Additionally, this study will target the higher expression of receptor SLC7A11, which is important in cancer survival, by incorporating the drug Sulfasalazine.5
The ND-ACES NSF Track-1 cooperative agreement is a federal-state partnership to manage a comprehensive research development plan. ND EPSCoR manages the Track-1 award. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation. Current funding is provided by the State of North Dakota and NSF EPSCoR Research Infrastructure Improvement Program Track-1 (RII Track-1) Cooperative Agreement Award OIA #1946202.